Raziel Therapeutics

Raziel Therapeutics, founded in 2012, is a clinical-stage pharmaceutical company based in Israel. The company focuses on developing proprietary drugs for localized fat reduction in obese patients. Raziel offers a revolutionary solution for focal fat reduction with its proprietary lipolytic injectable compound. This one-time, non-surgical treatment addresses both aesthetic and therapeutic needs. Raziel has signed a commercial licensing agreement with Fosun Pharma for the Chinese market, targeting its first application in submental fat (commonly known as double chin).